Celcuity Inc. has unveiled a corporate presentation highlighting the potential of their developmental therapy, gedatolisib, for treating cancers involving the PI3K/AKT/mTOR $(PAM)$ pathway. The presentation emphasizes the significant untapped opportunity in addressing breast and prostate cancers, which are associated with this oncogenic pathway. Gedatolisib's mechanism of action and pharmacokinetic profile contribute to its potency and tolerability as a PAM inhibitor. Ongoing clinical trials include a Phase 3 study for second-line (2L) patients with HR+/HER2- advanced breast cancer $(ABC.AU)$ and a recently initiated Phase 3 study for first-line (1L) patients. Celcuity Inc. is exploring potential applications of gedatolisib for prostate cancer, noting the parallels between breast and prostate cancer, particularly the interaction between PAM and hormonal pathways. With a substantial addressable patient population and limited market penetration of PAM drugs, the company is positioned to explore multiple indications. Celcuity's financial position includes $205 million in cash, cash equivalents, and short-term investments as of Q1 2025, supporting operations through 2026. You can access the full presentation through the link below.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。